Wegovy Pricing in the UK: What the Numbers Really Mean

The myth: the cheapest Wegovy listing is the best deal

A question our prescribers hear most weeks is some version of: "I've found it cheaper elsewhere, is it the same thing?" It's a completely reasonable thing to ask. The honest answer is: sometimes yes, often no, and you usually can't tell from the price alone.

The biggest misconception about Wegovy pricing in the UK is that providers are selling a commodity, like comparing petrol prices at forecourts. They're not. Wegovy is a prescription medicine, and the prescription process itself is the thing that makes the medicine safe for you specifically. A quote that strips out the consultation fee, the clinical review, ongoing prescriber support, and tracked delivery isn't a like-for-like comparison. It's an incomplete price for an incomplete service.

The MHRA has warned publicly that fake weight-loss pens are being sold online, some containing harmful substances including insulin. Providers offering these medicines without a proper clinical assessment are a red flag, not a bargain. You can check any online pharmacy against the GPhC register before you commit to anything. Our approach to dispensing and clinical oversight is built around that verification layer.

What actually drives Wegovy pricing in the UK

Wegovy is dispensed in five dose steps: 0.25mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg. Pricing typically reflects the dose, because higher-dose pens cost more to manufacture and supply. Private providers price per pen or per four-week supply, so a patient in the early titration phase pays less than someone established on the 2.4mg maintenance dose.

Supply-chain economics shifted notably in late 2025. Eli Lilly's September 2025 list-price increase on Mounjaro pushed the wider market to recalibrate, and Wegovy pricing has moved in parallel as Novo Nordisk manages distribution across a growing number of countries. When you see pricing described on any provider's page, it is worth checking whether the figure is current, as of summer 2026, typical private monthly pricing for Wegovy sits in the £149–£375 range depending on dose, as widely reported. If you're looking specifically at Wegovy prive options, our dedicated page covers what those private supply arrangements involve. For a detailed look at what specific supply costs, our Wegovy cost breakdown page goes into this in more granular terms.

Beyond the pen itself, legitimate pricing covers: a clinical consultation (which for a prescription medicine is not optional), the prescription fee, dispensing, and delivery. At nume, those are all included in one figure. No subscription, no auto-renewal, and a prescriber reviews every repeat order before it goes out. If a price you find elsewhere excludes any of those, add them back in before comparing.

What NICE says, and why it affects who pays what

Wegovy has a NICE recommendation for use in adults with a BMI of 35 or above plus at least one weight-related health condition, within a specialist weight management service and for a maximum of two years. Lower BMI thresholds apply for some ethnic backgrounds under NICE's appraisal of semaglutide (TA875). On the NHS, eligibility criteria are strict and waiting lists are long, which is why a significant number of adults are choosing the private route.

For private prescribing, the licensed eligibility criteria are broader: adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. A prescriber assesses the full picture, not just the BMI number. Meeting the BMI threshold is a starting point, not a guarantee of approval. You can read more about semaglutide and how it works to understand what the clinical assessment is looking for.

The NHS route through specialist services remains an option for those who qualify, and it is worth exploring through your GP. The private route exists for people who don't meet NHS criteria yet, or who don't want to wait. Neither is the wrong answer, the right one depends on your circumstances. Our Wegovy treatment overview sets out both routes clearly.

Pricing and the newer Wegovy options: 7.2mg pen and oral tablets

Since early 2026, Wegovy's licensed options in the UK have expanded. The MHRA approved a dedicated single-dose 7.2mg pen in April 2026 for adults with a BMI of 30 or above, offering a higher maintenance ceiling than the previous 2.4mg standard. Clinical trial data reported around 20.7% average weight loss over 72 weeks at the 7.2mg dose, which narrows the gap with tirzepatide results. Pricing for this higher-dose format is still settling across the market.

Separately, oral semaglutide tablets (Wegovy tablets) received MHRA approval in June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management. The trial evidence showed roughly 13.6% average weight loss over 64 weeks versus placebo, with around 17% among participants who stayed fully adherent to treatment. If you're weighing the injection against the tablet on cost and practicality, our timeline of Wegovy's UK approvals gives useful context on availability. Specific dose and format availability is always confirmed at consultation, since supply can vary.

The guidance on injection timing and spacing is set by your prescriber based on your dose history, not by the pricing tier you're on. Dose progression is a clinical decision, not a commercial one. If you're ready to understand which option fits your situation, speaking to our prescribers is the next step.